Goldman Sachs's Rating Change Only Had Short-term Impact, AstraZeneca Up 3.8% (AZN)

A week ago, Goldman Sachs downgraded AstraZeneca from Neutral to Sell. AstraZeneca shares are selling at $30.20, 3.8% above the $29.09 price point of one week ago.Potential upside of...